Method for extracting progesterone from phytosterol fermentation liquor
Through multi-step extraction and crystallization purification technology, progesterone is efficiently extracted from phytosterol fermentation broth, solving the problem of purification difficulties in the existing process, achieving high-purity and high-yield progesterone production, reducing costs and increasing Environmental protection.
Patent Information
- Application Number
- CN202411065155.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-22
AI Technical Summary
In the existing progesterone biosynthesis process, the purification process of progesterone in the fermentation broth is difficult, resulting in high production costs, high environmental pollution and poor product quality.
The extraction and concentration of different solvents were performed using multiple steps of extraction, concentration and crystallization from the phytosterol fermentation broth, including preliminary extraction using ester, ether and chlorinated solvents, followed by second use of alcohol and acetonitrile. Sub-extraction, concentrated by low temperature treatment and rotary evaporation, and finally high purity progesterone was obtained by crystallization.
It achieves high yield and high purity extraction of progesterone, reduces production costs, is suitable for large-scale industrial production, and has good environmental protection.
Smart Images

Figure HDA0004979136870000011 
Figure HDA0004979136870000012 
Figure HDA0004979136870000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of progesterone biosynthesis and purification, and particularly relates to a method for extracting progesterone from a phytosterol fermentation broth. Background Art
[0002] Progesterone, also known as progesterone hormone or luteinizing hormone, is the main biologically active progestogen secreted by the ovaries and plays an important role in human reproduction. It is mainly used clinically for symptoms such as habitual abortion, dysmenorrhea, excessive menstrual bleeding or metrorrhagia, and amenorrhea. In recent years, the clinical application scope of progesterone has been continuously expanded, and the demand has shown an upward trend.
[0003] At present, the synthesis of progesterone in industry mainly uses acetic acid gestionenolone as raw material, and progesterone is synthesized by hydrogenation, ester hydrolysis, and finally secondary alcohol oxidation. The raw material source of this method is difficult, the process is complicated, the cost is high, the environmental pollution is large, and the post-processing is difficult. Industry practitioners have also reported other greener synthesis processes. The biosynthesis of progesterone by microbial fermentation using plant sterols as raw materials is simple, low-cost, and has little environmental pollution. It is a greener progesterone synthesis process. However, how to separate and purify progesterone in the fermentation broth is a technical problem that needs to be solved urgently. Summary of the invention
[0004] The purpose of the present invention is to provide a purification scheme with high extraction yield and good product quality to address the gap in the purification and extraction scheme in the new process route of progesterone biosynthesis.
[0005] To achieve the above technical objectives, in one aspect, the present disclosure provides a method for extracting progesterone from a phytosterol fermentation broth, comprising the following steps:
[0006] A method for extracting progesterone from phytosterol fermentation broth, characterized in that it comprises the following steps:
[0007] S1: adding extraction solvent I to the phytosterol fermentation broth to obtain extraction phase I;
[0008] S2: concentrating the extract phase I to obtain a concentrated phase I;
[0009] S3: adding extraction solvent II to the concentrated phase I to obtain extraction phase II;
[0010] S4: cooling the extraction phase II to -20 to 25° C., removing the lower oil phase, and obtaining the deoiled extraction phase II;
[0011] S5: concentrating the deoiled extract phase II to obtain a concentrated phase II;
[0012] S6: Purify the concentrated phase II by crystallization to obtain the target product.
[0013] According to any of the foregoing aspects, the extraction solvent I is selected from one or more of esters, ethers, hydrocarbons, ketones, nitro compounds, thioethers and chlorinated solvents. In some embodiments, the extraction solvent I is selected from esters, such as ethyl acetate, butyl acetate, isoamyl acetate, isobutyl acetate, propyl acetate; ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane, diisopropyl ether, tert-butyl methyl ether; chlorinated solvents, such as chloroform, dichloromethane, 1,2-dichloroethane, chlorobenzene, trichloroethylene and other water-immiscible solvents. In addition to the esters, ethers and chlorinated solvents listed above, other solvents that are immiscible with water include: esters, such as ethyl propionate, butyl propionate, methyl propionate, isopropyl acetate; ethers, such as cyclohexane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether; chlorinated solvents, such as carbon tetrachloride, chloroform; hydrocarbons, such as petroleum ether, n-hexane, isohexane, cyclopentane; aromatic hydrocarbons, such as benzene, toluene, xylene; ketones, such as methyl isobutyl ketone, cyclohexanone; nitro compounds, such as nitrobenzene; sulfides, such as dimethyl sulfide.
[0014] According to any of the foregoing aspects, the extraction solvent II is selected from one or more of alcohols and acetonitrile. In some embodiments, the extraction solvent II is selected from one or more of alcohols containing 1 to 10 carbon atoms, preferably alcohols containing 1 to 6 carbon atoms, such as methanol, ethanol, n-propanol, tert-butanol, isopropanol, isobutanol and n-butanol and mixtures thereof. In some preferred embodiments, the extraction solvent II is acetonitrile.
[0015] According to any of the foregoing aspects, the step of low-temperature treatment of the extraction phase II comprises transferring the extraction phase II to a jacketed glass kettle, lowering the temperature to -20 to 25°C, preferably -10 to 10°C, more preferably -10 to 5°C, maintaining for 2 to 4 hours, removing the lower oil phase, and obtaining the deoiled extraction phase II. In some embodiments, the extraction phase II is transferred to a jacketed glass kettle, lowering the temperature to -20°C, -15°C, -10°C, -5°C, -3°C, 0°C, 2°C, 5°C, 8°C, 10°C, 12°C, 15°C, 20°C, or 25°C, maintaining for 2, 3 or 4 hours, removing the lower oil phase, and obtaining the deoiled extraction phase II.
[0016] According to any of the foregoing aspects, the weight ratio of the extraction solvent I to the phytosterol fermentation broth is 0.3 to 0.8: 1, preferably 0.4 to 0.6, and more preferably 0.5: 1. In some embodiments, 0.3, 0.4, 0.5, 0.6, 0.7 or 0.8 parts by weight of the extraction solvent I is added to 1 part by weight of the phytosterol fermentation broth, stirred at room temperature for 5, 6, 7, 8, 9 or 10 minutes, and allowed to stand for about 0.5 hours, and then separated by layers to obtain the extraction phase I.
[0017] According to any of the foregoing aspects, the concentration step of the extraction phase I is rotary evaporation, the rotary evaporation temperature is 30-80°C, preferably 40-60°C, more preferably 40-55°C, the rotary evaporation vacuum is 10-1000mbar, preferably 40-200mbar, more preferably 60-100mbar, and the rotary evaporation time is 1-2 hours. In some embodiments, the extract phase I is transferred to a rotary evaporator at a temperature of 30°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C or 80°C and a vacuum degree of 10mbar, 20mbar, 40mbar, 60mbar, 80mbar, 100mbar, 150mbar, 200mbar, 250mbar, 300mbar, 400mbar, 500mbar, 600mbar, 700mbar, 800mbar, 900mbar or 1000mbar. The rotary evaporator is performed for 1 hour, 1.5 hours or 2 hours until no liquid drips out, and the rotary evaporator is stopped to obtain the concentrated phase I.
[0018] According to any of the above aspects, the extractant II is added to the concentrated phase I in four times, and the weight ratio of the extractant II added each time to the concentrated phase is 0.5 to 2.0: 1, preferably 1.0 to 1.5: 1. In some embodiments, the extractant II is added to the concentrated phase I in four times, and the weight ratio of the extractant II added each time to the concentrated phase II is 0.5: 1, 0.8: 1, 1: 1, 1.2: 1, 1.5: 1 or 2.0: 1, after stirring at room temperature for 5, 6, 7, 8, 9 or 10 minutes, it is allowed to stand for about 0.5 hours, and the extract phase II is obtained by layering.
[0019] According to any of the aforementioned aspects, the step of concentrating the deoiled extract phase II is rotary evaporation, the rotary evaporation temperature is 30-80°C, preferably 40-65°C, more preferably 40-60°C, the rotary evaporation vacuum is 10-1000mbar, preferably 20-200mbar, and the rotary evaporation time is 1-2 hours. In some embodiments, the deoiled extract phase II is transferred to a rotary evaporator at a temperature of 30°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C or 80°C and a vacuum degree of 10mbar, 20mbar, 40mbar, 60mbar, 80mbar, 100mbar, 150mbar, 200mbar, 250mbar, 300mbar, 400mbar, 500mbar, 600mbar, 700mbar, 800mbar, 900mbar or 1000mbar. The rotary evaporation is performed for 1 hour, 1.5 hours or 2 hours until no liquid drips out, and the rotary evaporation operation is stopped to obtain a concentrated phase II.
[0020] According to any of the aforementioned aspects, the crystallization purification step comprises: (1) adding a crystallization solvent I and an anti-solvent I to the concentrated phase II, cooling and crystallizing to obtain a primary crystallization crude product; (2) adding a crystallization solvent II to the primary crystallization crude product, cooling and crystallizing to obtain a secondary crystallization fine product.
[0021] According to any of the foregoing aspects, the weight ratio of the crystallization solvent I to the concentrated phase II is 0.2 to 2.0:1, preferably 0.2 to 1.0:1, the weight ratio of the antisolvent I to the concentrated phase II is 0.5 to 5.0:1, preferably 0.5 to 1.0:1; the weight ratio of the crystallization solvent II to the crude primary crystallization product is 2.0 to 10.0:1, preferably 2.0 to 5.0:1.
[0022] According to any of the foregoing aspects, after adding the crystallization solvent I and the antisolvent I to the concentrated phase II, the material is transferred to the crystallization kettle, the temperature is reduced to -10 to 10°C, preferably -5 to 5°C, and maintained for 4 to 10 hours, preferably about 6 hours, the crystallization liquid is filtered and washed to obtain a wet cake, and vacuum dried at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain a primary crystallization crude product; the crystallization solvent II is added to the primary crystallization crude product, the temperature is reduced to -10 to 10°C, maintained for 4 to 10 hours, preferably about 6 hours, the crystallization liquid is filtered and washed to obtain a wet cake, and vacuum dried at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain the secondary crystallization fine product.
[0023] In some embodiments, 0.2, 0.5, 0.8, 1.0, 1.2, 1.5 or 2.0 parts by weight of crystallization solvent I and 0.5, 0.8, 1.0, 1.5, 2.0, 3.0, 4.0 or 5.0 parts by weight of antisolvent I are added to 1 part by weight of concentrated phase II, and after the material is transferred to a crystallization kettle, the temperature is reduced to -10°C, -8°C, -5°C, -2°C, 0°C, 2°C, 5°C, 8°C, 10°C and maintained for 4, 5, 6, 7, 8, 9 or 10 The crystalline liquid is filtered and washed to obtain a wet cake, which is then transferred to a vacuum oven at a temperature of 40°C, 50°C or 60°C and a vacuum degree of 100 mbar, 200 mbar, 300 mbar, 400 mbar, 500 mbar, 600 mbar, 700 mbar, 800 mbar, 900 or 1000 mbar, and vacuum dried for 10, 11, 12, 13, 14 or 15 hours to obtain a crude primary crystal.
[0024] In some embodiments, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 parts by weight of crystallization solvent II is added to 1 part by weight of the primary crystallization crude product, and after the material is transferred to the crystallization kettle, the temperature is reduced to -10°C, -8°C, -5°C, -2°C, 0°C, 2°C, 5°C, 8°C, 10°C, and maintained for about 4, 5, 6, 7, 8, 9 or 10 hours, and the crystallization liquid is filtered and washed to obtain a wet The filter cake is transferred to a vacuum oven at a temperature of 40°C, 50°C or 60°C and a vacuum degree of 100 mbar, 200 mbar, 300 mbar, 400 mbar, 500 mbar, 600 mbar, 700 mbar, 800 mbar, 900 or 1000 mbar, and vacuum dried for 10, 11, 12, 13, 14 or 15 hours to obtain a secondary crystallized fine product, which is the target product.
[0025] According to any of the foregoing aspects, the crystallization solvent I is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate, and the antisolvent I is selected from one or more of long-chain normal or isoalkanes. In some embodiments, the antisolvent I is selected from normal or isoalkanes containing 6 to 15 carbon atoms, such as n-hexane, n-heptane, isohexane, n-nonane, n-decane and isodecane, and mixtures thereof.
[0026] According to any of the above aspects, the crystallization solvent II is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate. According to any of the above aspects, after the crystallization purification step, a crystallization mother liquor application step is also included.
[0027] According to any of the above aspects, the step of applying the crystallization mother solution comprises:
[0028] (1) concentrating the mother crystallization mother liquor to obtain a concentrated phase III, adding the crystallization solvent I and the antisolvent I to the concentrated phase III, lowering the temperature to -10 to 10°C, maintaining for 4 to 10 hours, preferably about 6 hours, filtering the crystallization liquid to obtain a wet cake, and vacuum drying at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain a crude primary crystallization product;
[0029] (2) Add the crystallization solvent II to the crude product of the applied primary crystallization, reduce the temperature to -10 to 10°C, maintain for 4 to 10 hours, preferably about 6 hours, filter the crystallization liquid to obtain a wet filter cake, and vacuum dry to obtain a fine product of the applied secondary crystallization.
[0030] In some embodiments, the mother liquors of the primary crystallization and the secondary crystallization are combined, transferred to a rotary evaporator, and vacuum concentrated to obtain a concentrated phase III. 0.2, 0.5, 0.8, 1.0, 1.2, 1.5 or 2.0 parts by weight of the crystallization solvent I and 0.5, 0.8, 1.0, 1.5, 2.0, 3.0, 4.0 or 5.0 parts by weight of the antisolvent I are added to 1 part by weight of the concentrated phase III, and the material is transferred to a crystallization kettle, and the temperature is reduced to -10°C, -8°C, -5°C, -2°C, 0°C, 2°C, 5°C, 8°C, 10°C, and maintained for about 4, 5, 6, 7, 8, 9 or 10 hours. The crystallization liquid is filtered and washed to obtain a wet filter cake, and the filter cake is transferred to a vacuum oven at a temperature of 40°C, 50°C or 60°C and a vacuum degree of 100 mbar, 200 mbar, 300 mbar, 400 mbar, 500 mbar, 600 mbar, 700 mbar, 800 mbar, 900 or 1000 mbar, and vacuum dried for 10, 11, 12, 13, 14 or 15 hours to obtain a crude primary crystallization product. To 1 part by weight of the crude primary crystallization product, add 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, or 10.0 parts by weight of the crystallization solvent II, transfer the material to a crystallization kettle, reduce the temperature to -10°C, -8°C, -5°C, -2°C, 0°C, 2°C, 5°C, 8°C, 10°C, and maintain for about 4, 5, 6, 7, 8, 9, or 10 hours, filter the crystallization liquid and wash to obtain a wet filter cake, transfer the filter cake to a vacuum oven at a temperature of 40°C, 50°C, or 60°C and a vacuum degree of 100 mbar, 200 mbar, 300 mbar, 400 mbar, 500 mbar, 600 mbar, 700 mbar, 800 mbar, 900, or 1000 mbar, and vacuum dry for 10, 11, 12, 13, 14, or 15 hours to obtain a fine secondary crystallization product. The target product is obtained by accumulating and applying the secondary crystallization products, and the final separation and purification yield is calculated.
[0031] In one aspect, the present disclosure provides a method for extracting progesterone from a phytosterol fermentation broth, comprising the following steps:
[0032] (1) adding an extraction solvent I to the phytosterol fermentation broth for a first extraction and concentration to obtain a concentrated phase I, wherein the extraction solvent I is selected from one or more of esters, ethers and chlorinated solvents;
[0033] (2) adding an extraction solvent II to the concentrated phase I for a second extraction to obtain an extraction phase II, wherein the extraction solvent II is selected from one or more of alcohols and acetonitrile;
[0034] (3) cooling the extract phase II to -20 to 25° C., removing the lower oil phase, and obtaining the deoiled extract phase II;
[0035] (4) Concentrating and crystallizing the deoiled extract phase II to obtain a first crystalline solid containing progesterone.
[0036] In some embodiments, in step (1), the extraction solvent I is selected from ethyl acetate.
[0037] In some embodiments, the extraction solvent I is selected from esters, such as ethyl acetate, butyl acetate, isoamyl acetate, isobutyl acetate, and propyl acetate; ethers, such as diethyl ether, tetrahydrofuran, 1,4-dioxane, diisopropyl ether, and tert-butyl methyl ether; chlorinated solvents, such as chloroform, dichloromethane, 1,2-dichloroethane, chlorobenzene, trichloroethylene, and other water-immiscible solvents.
[0038] In addition to the esters, ethers and chlorinated solvents listed above, other solvents that are immiscible with water include: esters, such as ethyl propionate, butyl propionate, methyl propionate, isopropyl acetate; ethers, such as cyclohexane, diethylene glycol dimethyl ether, ethylene glycol dimethyl ether; chlorinated solvents, such as carbon tetrachloride, chloroform; hydrocarbons, such as petroleum ether, n-hexane, isohexane, cyclopentane; aromatic hydrocarbons, such as benzene, toluene, xylene; ketones, such as methyl isobutyl ketone, cyclohexanone; nitro compounds, such as nitrobenzene; sulfides, such as dimethyl sulfide.
[0039] In some embodiments, in step (1), the weight ratio of the extraction solvent I to the phytosterol fermentation broth is 0.3 to 0.8:1, preferably 0.4 to 0.8:1, and more preferably 0.5:1.
[0040] In some embodiments, in step (2), the extraction solvent II is selected from one or more alcohols containing 1 to 10 carbon atoms, preferably alcohols containing 1 to 6 carbon atoms, such as methanol, ethanol, n-propanol, tert-butanol, isopropanol, isobutanol and n-butanol and mixtures thereof.
[0041] In some embodiments, in step (2), the extraction solvent II is selected from acetonitrile.
[0042] In some embodiments, in step (2), the weight ratio of the extraction solvent II to the concentrated phase II is 2 to 8:1, preferably 4 to 6:1.
[0043] In some embodiments, the extraction solvent II is added in four times, and the weight ratio of the extraction solvent II added each time to the concentrated phase II is 0.5 to 2.0:1, preferably 1.0 to 1.5:1.
[0044] In some embodiments, in step (3), the extraction phase II is cooled to -10 to 10°C, preferably to -10 to 5°C.
[0045] In some embodiments, after step (4), the method further comprises the following steps: concentrating the crystallization mother liquor and then crystallizing to obtain a second crystalline solid containing progesterone.
[0046] In some embodiments, the crystallization comprises adding a crystallization solvent; preferably, the crystallization solvent is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate; more preferably, the crystallization solvent is selected from ethyl acetate and methanol. In some embodiments, the crystallization comprises two crystallizations:
[0047] (a) adding a crystallization solvent and an antisolvent to perform primary crystallization and drying to obtain a primary crystal crude product;
[0048] (b) adding a crystallization solvent to the crude primary crystal product for secondary crystallization and drying to obtain a secondary crystal product, which is a crystalline solid containing progesterone.
[0049] In some preferred embodiments, in step (a) and / or (b), the primary crystallization and / or secondary crystallization comprises: lowering the temperature to -10 to 10°C, preferably to -5 to 5°C, maintaining the temperature for more than 6 hours, and filtering the crystallization liquid to obtain a wet filter cake.
[0050] In some embodiments, the antisolvent comprises a long chain normal or isoalkane.
[0051] In some embodiments, the antisolvent I is selected from normal or isomeric alkanes containing 6 to 15 carbon atoms, for example, one or more selected from n-hexane, n-heptane, isohexane, n-nonane, n-decane, and isodecane.
[0052] In some preferred embodiments, the antisolvent is selected from n-heptane and n-hexane.
[0053] In some embodiments, in step (a), the weight ratio of the crystallization solvent to the concentrated phase is 0.2 to 2.0:1, preferably 0.2 to 1.0:1, and the weight ratio of the antisolvent to the concentrated phase is 0.5 to 5.0:1, preferably 0.5 to 1.0:1.
[0054] In some embodiments, in step (b), the weight ratio of the crystallization solvent to the crude product of the first crystallization is 2.0 to 10.0:1, preferably 2.0 to 5.0:1.
[0055] In some preferred embodiments, in step (a), the crystallization solvent comprises ethyl acetate; and in step (b), the crystallization solvent comprises methanol.
[0056] In some embodiments, the drying is vacuum drying; preferably, the vacuum drying temperature is 40-60° C.; preferably, the vacuum degree of the vacuum drying is 100-1000 mbar; preferably, the vacuum drying time is 10-15 hours.
[0057] In some embodiments, the concentration is rotary evaporation concentration; preferably, the rotary evaporation temperature is 30-80°C, more preferably 40-65°C; preferably, the rotary evaporation vacuum is 10-1000 mbar, more preferably 20-200 mbar; preferably, the rotary evaporation time is 1-2 hours.
[0058] The present disclosure has the following advantages:
[0059] (1) Provided for the first time a method for extracting progesterone from phytosterol fermentation broth;
[0060] (2) The materials used in the present disclosure are cheap and the steps are simple, which greatly reduces the production cost and is suitable for large-scale industrial production;
[0061] (3) The progesterone product extracted by the present invention has high quality purity and high yield. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] In order to more clearly illustrate the specific embodiments of the present disclosure or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the specific embodiments or the prior art description. Obviously, the drawings described below are some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can also be obtained based on these drawings without creative work. The drawings herein are incorporated into the specification and constitute a part of the specification, showing embodiments that conform to the specification, and are used together with the specification to explain the principles of the specification.
[0063] Figure 1 The gas chromatographic peak area graph of progesterone in the new Mycobacterium aureus strains transformed with different plasmids (P001-P007) in a 96-well plate is shown.
[0064] Figure 2 The gas chromatogram of the fermentation liquid is shown. The chromatogram is derived from the detection of the fermentation end point sample, the retention time of 3.190 min is progesterone, the retention times of 5.675 min, 5.987 min, and 6.629 min are phytosterol components, and the components with other retention times are fermentation by-products.
[0065] Figure 3The ethyl acetate phase gas chromatogram is shown. The chromatogram is derived from the detection of the upper ethyl acetate phase after the fermentation broth is extracted. The retention time of 3.148 min is progesterone, the retention times of 5.598 min, 5.908 min, and 6.540 min are phytosterol components, and the other retention time components are by-products. The figure shows that ethyl acetate plays a role in extracting phytosterols and progesterone analogs from the fermentation broth.
[0066] Figure 4 The acetonitrile phase gas chromatogram is shown. The chromatogram is derived from the sample of the ethyl acetate phase concentrate extracted by acetonitrile. The retention time of 3.143 min is progesterone, and the retention times of 2.612 min, 2.881 min, and 4.548 min are by-products. The figure shows that acetonitrile can effectively remove the incompletely converted phytosterols in the fermentation broth.
[0067] Figure 5 The gas chromatogram of the secondary crystallization product is shown. Among them: the chromatogram is from the progesterone sample after the secondary crystallization, and the progesterone is at a retention time of 3.1887min. The figure shows that after the secondary crystallization, the progesterone has reached a higher product purity. DETAILED DESCRIPTION
[0068] (I) Definition and Explanation
[0069] In order to make it easier to understand the present disclosure, some technical and scientific terms are specifically defined below. In the present disclosure, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the cell and tissue culture, microbiology-related terms and laboratory operation steps used herein are terms and routine steps widely used in the corresponding fields. At the same time, in order to better understand the present disclosure, the definition and explanation of the relevant terms are provided below. It should be understood that the present disclosure is not limited to specific methods, reagents, compounds, compositions or biological systems, and of course the above can be changed. It should also be understood that the terms used in the present application are only for describing specific embodiments and are not intended to be limited.
[0070] As used in this specification and the appended claims, the singular forms "a," "an," "the," "said," and similar referents include plural referents unless the content clearly dictates otherwise.
[0071] As used herein, the conjunction term "and / or" between various elements is intended to include both the meanings of "and" and "or", for example, the phrase "A, B and / or C" is intended to cover each of the following aspects: A, B and C; A, B or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0072] As used herein, the terms "comprises," "comprising," "having," and "containing," and any variations thereof, are intended to cover a non-exclusive inclusion. The terms are intended to be open ended, to specify the presence of any stated features, elements, integers, steps, or components, but not to preclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Thus, the term "comprising" encompasses the more restrictive terms "consisting of" and "consisting essentially of."
[0073] Numerical ranges used herein should be understood to include all numbers within the range. For example, a range of 1 to 20 should be understood to include any number, combination of numbers, or subrange from the following group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20.
[0074] As used herein, the term "about" means a range of ±20% of the value that follows. In some embodiments, the term "about" means a range of ±10% of the value that follows. In some embodiments, the term "about" means a range of ±5% of the value that follows.
[0075] In the description herein, reference is made to “some embodiments”, “some implementation schemes” or “some implementation plans”, which describe a subset of all possible embodiments, but it can be understood that “some embodiments” may be the same subset or different subsets of all possible embodiments and may be combined with each other without conflict.
[0076] As used herein, the term "phytosterol", also known as plant sterol, belongs to plant steroid compounds. The main components of phytosterols include sitosterol, campesterol, stigmasterol, rapeseed sterol and corresponding alkanols, all of which are based on cyclopentane perhydrophenanthrene and contain alcohol groups. The difference between them and cholesterol in structure is that there are more side chains on C24, such as sitosterol has an ethyl group on C24, campesterol has a methyl group on C24, and the structure of stigmasterol is the same as sitosterol, except that there is a double bond on C22. Plant foods with high phytosterol content include vegetable oils, nuts and seeds, beans, etc. The phytosterol content in vegetable oils is the highest in corn germ oil, followed by sesame oil; the content of pistachios in nuts and seeds is the highest, followed by black sesame; the content of soybeans in beans is the highest, followed by green beans; the content of phytosterols in vegetables, fruits and potatoes is relatively low. The relative density of phytosterols is slightly greater than that of water. It is insoluble in water, acid and alkali, but soluble in a variety of organic solvents, such as ether, benzene, chloroform, ethyl acetate, carbon disulfide and petroleum ether. The physical and chemical properties of phytosterols are mainly hydrophobic, but because of the hydroxyl groups in its structure, it is also hydrophilic, so phytosterols have emulsifying properties. Phytosterols obtained by solvent crystallization are usually needle-shaped white crystals, and their commercial products are mostly powder or flakes. The relative molecular mass of phytosterols is about 386-456Da, and the melting point is relatively high, all exceeding 100°C, and the highest is 215°C.
[0077] (II) Detailed technical solution
[0078] In a specific embodiment, the present disclosure provides a method for extracting progesterone from a phytosterol fermentation broth, comprising the following steps:
[0079] (1) adding an extraction solvent I to the phytosterol fermentation broth for a first extraction and concentration to obtain a concentrated phase I, wherein the extraction solvent I is selected from one or more of esters, ethers and chlorinated solvents;
[0080] (2) adding an extraction solvent II to the concentrated phase I for a second extraction to obtain an extraction phase II, wherein the extraction solvent II is selected from one or more of alcohols and acetonitrile;
[0081] (3) cooling the extract phase II to -20 to 25° C., removing the lower oil phase, and obtaining the deoiled extract phase II;
[0082] (4) Concentrating and crystallizing the deoiled extract phase II to obtain a first crystalline solid containing progesterone.
[0083] In some embodiments, in step (1), the extraction solvent I comprises ethyl acetate.
[0084] In some embodiments, in step (1), the weight ratio of the extraction solvent I to the phytosterol fermentation broth is 0.3 to 0.8:1, preferably 0.4 to 0.8:1.
[0085] In some embodiments, in step (2), the extraction solvent II comprises acetonitrile.
[0086] In some embodiments, in step (2), the weight ratio of the extraction solvent II to the concentrated phase I is 2 to 8:1, preferably 4 to 6:1.
[0087] In some embodiments, the extraction solvent II is added in four times, and the weight ratio of the extraction solvent II added each time to the concentrated phase I is 0.5-2.0:1, preferably 1.0-1.5:1.
[0088] In some embodiments, in step (3), the extraction phase II is cooled to -10 to 10°C, preferably to -10 to 5°C.
[0089] In some embodiments, after step (4), the method further comprises the following steps: concentrating the crystallization mother liquor and then crystallizing to obtain a second crystalline solid containing progesterone.
[0090] The accumulation of the first crystalline solid and the second crystalline solid containing progesterone is the final progesterone extraction product.
[0091] In some embodiments, the crystallization comprises adding a crystallization solvent; preferably, the crystallization solvent is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate; more preferably, the crystallization solvent is selected from ethyl acetate and methanol.
[0092] In some embodiments, the crystallization comprises two crystallizations:
[0093] (a) adding a crystallization solvent and an antisolvent to perform primary crystallization and drying to obtain a primary crystal crude product;
[0094] (b) adding a crystallization solvent to the crude primary crystal product for secondary crystallization and drying to obtain a secondary crystal product, which is a crystalline solid containing progesterone.
[0095] In some preferred embodiments, in step (a) and / or (b), the primary crystallization and / or secondary crystallization comprises: lowering the temperature to -10 to 10°C, preferably to -5 to 5°C, maintaining the temperature for more than 6 hours, and filtering the crystallization liquid to obtain a wet filter cake.
[0096] In some embodiments, the antisolvent comprises a long chain normal or isoalkane.
[0097] In some preferred embodiments, the antisolvent is selected from n-heptane and n-hexane.
[0098] In some embodiments, in step (a), the weight ratio of the crystallization solvent to the concentrated phase is 0.2 to 2.0:1, preferably 0.2 to 1.0:1, and the weight ratio of the antisolvent to the concentrated phase is 0.5 to 5.0:1, preferably 0.5 to 1.0:1.
[0099] In some embodiments, in step (b), the weight ratio of the crystallization solvent to the crude primary crystallization product is 2.0 to 10.0:1, preferably 2.0 to 5.0:1.
[0100] In some preferred embodiments, in step (a), the crystallization solvent comprises ethyl acetate; and in step (b), the crystallization solvent comprises methanol.
[0101] In some embodiments, the drying is vacuum drying; preferably, the vacuum drying temperature is 40-60° C.; preferably, the vacuum degree of the vacuum drying is 100-1000 mbar; preferably, the vacuum drying time is 10-15 hours.
[0102] In some embodiments, the concentration is rotary evaporation concentration; preferably, the rotary evaporation temperature is 30-80°C, more preferably 40-65°C; preferably, the rotary evaporation vacuum is 10-1000 mbar, more preferably 20-200 mbar; preferably, the rotary evaporation time is 1-2 hours.
[0103] In some preferred embodiments of the present disclosure, a method for extracting progesterone from a phytosterol fermentation broth is provided, comprising the following steps:
[0104] (1) Extraction of fermentation broth:
[0105] 0.3-0.8 parts by weight of extraction solvent I was added to 1 part by weight of fermentation liquid, and the mixture was stirred at room temperature for 5-10 minutes, and then allowed to stand for about 0.5 hours, and then separated into layers to obtain extraction phase I.
[0106] Preferably, the extractant I comprises a water-immiscible system such as esters, ethers, and chlorinated solvents, and the weight ratio of the extractant I to the fermentation broth is 0.4-0.6:1.
[0107] (2) Concentration of extract phase I:
[0108] The extraction phase I is transferred to a rotary evaporation bottle at a rotary evaporation temperature of 30 to 80° C. and a rotary evaporation vacuum of 10 to 1000 mbar. The rotary evaporation is performed for 1 to 2 hours until no liquid drips out, and then the rotary evaporation operation is stopped to obtain a concentrated phase I.
[0109] Preferably, the rotary evaporation temperature is 40-55° C., and the rotary evaporation vacuum degree is 40-200 mbar.
[0110] (3) Extraction of concentrated phase I:
[0111] The extractant II was added to the concentrated phase I in four portions, with the weight ratio of the extractant II to the concentrated phase I being 0.5-2.0:1 each time. After stirring at room temperature for 5-10 minutes, the mixture was allowed to stand for about 0.5 hour and separated by layers to obtain the extract phase II.
[0112] Preferably, the extractant II comprises solvents such as alcohols and acetonitrile, and the weight ratio of the extractant II to the concentrated phase I is 1.0-1.5:1.
[0113] (4) Low temperature degreasing:
[0114] The extract phase II was transferred to a jacketed glass reactor, the temperature was lowered to -20 to 25°C, and maintained for 2 to 4 hours, and the lower oil phase was removed to obtain the deoiled extract phase II.
[0115] Preferably, the temperature is 0-10°C.
[0116] (5) Concentration of extract phase II after degreasing:
[0117] The deoiled extract phase II is transferred to a rotary evaporator at a temperature of 30 to 80°C and a vacuum degree of 10 to 1000 mbar. The rotary evaporator is operated for 1 to 2 hours until no more liquid drips out, and the rotary evaporator is stopped to obtain a concentrated phase II.
[0118] Preferably, the rotary evaporation temperature is 40-65° C., and the rotary evaporation vacuum degree is 20-200 mbar.
[0119] (6) Primary crystallization crude product:
[0120] To 1 part by weight of concentrated phase II, add 0.2-2.0 parts by weight of crystallization solvent I and 0.5-5.0 parts by weight of antisolvent I. After the material is transferred to the crystallization kettle, the temperature is reduced to -10-10°C and maintained for about 6 hours, the crystallization liquid is filtered and washed to obtain a wet cake, which is vacuum dried at 40-60°C and 100-1000 mbar for 10-15 hours to obtain a crude primary crystal.
[0121] Preferably, the crystallization solvent I is a solvent such as methanol, ethanol, isopropanol, ethyl acetate, acetone, n-butyl acetate, etc., and the weight ratio of the crystallization solvent I to the concentrated phase II is 0.2 to 1.0:1; the antisolvent I is a long-chain normal or isoalkane, and the weight ratio of the antisolvent I to the concentrated phase II is 0.5 to 1.0:1; the crystallization temperature is -5 to 5°C.
[0122] (7) Secondary crystallization products:
[0123] Add 2.0-10.0 parts by weight of crystallization solvent II to 1 part by weight of the primary crystallization crude product. After the material is transferred to the crystallization kettle, the temperature is reduced to -10-10°C and maintained for about 6 hours. The crystallization liquid is filtered and washed to obtain a wet cake, which is then vacuum dried at 40-60°C and 100-1000 mbar for 10-15 hours to obtain a secondary crystallization product.
[0124] Preferably, the crystallization solvent II is methanol, ethanol, isopropanol, ethyl acetate, acetone, n-butyl acetate and the like, and the weight ratio of the crystallization solvent II to the primary crystallization crude product is 2.0-5.0:1.
[0125] (8) Application of crystallization mother liquor:
[0126] The mother liquors of the primary crystallization and the secondary crystallization are combined, transferred to a rotary evaporator, and vacuum concentrated to obtain a concentrated phase III. To 1 weight part of the concentrated phase III, 0.2 to 2.0 weight parts of the crystallization solvent I and 0.5 to 5.0 weight parts of the antisolvent I are added. After the material is transferred to the crystallization kettle, the temperature is reduced to -10 to 10°C and maintained for about 6 hours. The crystallization liquid is filtered and washed to obtain a wet cake, which is vacuum dried at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain a crude primary crystallization product.
[0127] Add 2.0-10.0 parts by weight of crystallization solvent II to 1 part by weight of crude primary crystallization product. After the material is transferred to the crystallization kettle, the temperature is reduced to 10-10°C and maintained for about 6 hours. The crystallization liquid is filtered and washed to obtain a wet cake, which is vacuum dried at 40-60°C and 100-1000 mbar for 10-15 hours to obtain a fine secondary crystallization product.
[0128] The final separation and purification yield is calculated by accumulating the fine product yields in steps (7) and (8).
[0129] Any microorganism that can be used to express the introduced gene can be modified for fermentation production of progesterone as described above. In some embodiments, the microbial cell of the present disclosure may be a microbial cell disclosed in WO2024131933A1. In certain embodiments, the microorganism is an engineered microorganism that can ferment and produce progesterone. On the one hand, the present disclosure relates to a modified microbial cell that produces progesterone, and in certain embodiments, the modified microbial cell expresses: (a) a non-native side chain cleavage P450 enzyme; and (b) one or more non-native redox chaperones. In certain embodiments, the one or more non-native redox chaperones comprise a non-native ferredox protein and / or a non-native ferredox protein reductase. In certain embodiments, the non-native side chain cleavage P450 enzyme has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with any one of SEQ ID NOs: 1-4 and 7-24. In certain embodiments, the non-native ferredoxin has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to any one of SEQ ID NOs: 5, 25-37, and 48. In certain embodiments, the non-native ferredoxin reductase has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid sequence identity to any one of SEQ ID NOs: 6, 38-47. In certain embodiments, the non-native side-chain cleavage P450 enzyme has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity to a Novosphingobium sp. PP1Y side-chain cleavage P450 enzyme (e.g., SEQ ID NO: 18) or a Novosphingobium subterraneum side-chain cleavage P450 enzyme (e.g., SEQ ID NO: 1).
[0130] In certain embodiments, the microorganism is an easily culturable microorganism, for example, a microorganism known to be used as a host cell in the fermentation production of a target compound. Bacterial cells, including Gram-positive or Gram-negative bacteria, can be modified as described above. Examples include C. glutamicum, Bacillus subtilus, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. resistant Bacillus halodurans, Bacillus megaterium, Bacillus coagulans, Bacillus circulans, Bacillus lautus, Bacillus thuringiensis, Streptomyces albus, Streptomyces lividans, Streptomyces coelicolor, Streptomyces griseus, Pseudomonas sp.) (e.g., Pseudomonas putida), Pseudomonas alcaligenes, P. citrea, Lactobacillus spp. (e.g., Lactococcus lactis, Lactobacillus plantarum, L. grayi, E. coli, E. faecium, E. gallinarum, E. casseliflavus, and / or E. faecalis cells.
[0131] In certain embodiments, the microorganism or microbial cell described in the present disclosure is a mycobacterium (Mycobacterium) strain. In certain embodiments, the microorganism or microbial cell described in the present disclosure is a new gold mycobacterium (Mycobacterium neoaurum) (for example, new gold mycobacterium NRRL B-3805). In certain embodiments, the microorganism or microbial cell described in the present disclosure is a mycobacterium (Mycobacterium spp.) strain (for example, Mycolicibacter smegmatis (Mycolicibacter smegmatis), new gold mycobacterium (Mycobacterium neoaurum) or fortuitum (Mycolicibacter fortuitum)). In certain embodiments, the microorganism or microbial cell described in the present disclosure is a strain of Rhodococcus spp. (e.g., Rhodococcus jostii, Rhodococcus rhodochrous, Rhodococcus erythropolis, Rhodococcus jostii, or Rhodococcus ruber). In certain embodiments, the microorganism or microbial cell described in the present disclosure is a strain of Nocardia spp. (e.g., Nocardia corallina, Nocardia corallina, or Nocardia opaca).
[0132] There are many types of anaerobic cells that can be used as microbial host cells in the methods of the present disclosure. In certain embodiments, the microbial cells are obligate anaerobic cells. Obligate anaerobes are not usually well grown under conditions where oxygen is present (if any). Of course, a small amount of oxygen may be present, that is, obligate anaerobes have a certain degree of tolerance to low levels of oxygen. Obligate anaerobes modified as described above can be grown under substantially anaerobic conditions, wherein the amount of oxygen present is harmless to the growth, maintenance and / or fermentation of the anaerobic bacteria.
[0133] Alternatively, the microbial host cells used in the methods of the present disclosure can be facultative anaerobic cells. If oxygen is present, facultative anaerobes can produce cellular ATP by aerobic respiration (e.g., using the TCA cycle). However, facultative anaerobes can also grow in the absence of oxygen. Facultative anaerobes modified as described above can grow under substantially anaerobic conditions, wherein the amount of oxygen present is harmless to the growth, maintenance and / or fermentation of the anaerobic bacteria, or can grow in the presence of a greater amount of oxygen.
[0134] In certain embodiments, the microbial host cells used in the methods of the present disclosure are filamentous fungal cells (see, e.g., Berka & Barnett, Biotechnology Advances, (1989), 7(2): 127-154). Examples include Trichoderma longibrachiatum, T. viride, T. koningii, T. harzianum, Penicillium sp., Humicola insolens, H. lanuginose, H. grisea, Chrysosporium sp., C. lucknowense, Gliocladium sp., Aspergillus sp. (e.g., A. oryzae, A. niger, A. sojae, A. japonicus, A. nidulans, or A. awamori), Fusarium sp. sp.) (e.g., F. Roseum, F. graminum, F. grainis, F. oxysporuim, or F. venenatum)), Neurospora sp.) (e.g., N. crassa or Hypocrea sp.), Mucor sp.) (e.g., M. miehei), Rhizopus sp., and Emericella sp. cells. In a specific embodiment, the fungal cell of the above transformation is Aspergillus nidulans, A. awamori, A. oryzae, A. aculeatus, A. niger, A. japonicus, T. reesei, T. viride, F. oxysporuim or F. solani. Exemplary plasmids or plasmid components used with such hosts include those described in U.S. Patent Publication No. 2007 / 012013.
[0135] Yeast can also be used as a microbial host cell in the methods of the present disclosure. Examples include: Saccharomyces sp., Schizosaccharomyces sp., Pichia sp., Hansenula polymorpha, Pichia stipites, Kluyveromyces marxianus, Kluyveromyces spp., Yarrowia lipolytica, and Candida sp. In certain embodiments, Saccharomyces sp. is Saccharomyces cerevisiae (see, e.g., Romanos et al., Yeast, (1992), 8(6): 423-488). Exemplary plasmids or plasmid components for use with such hosts include those described in U.S. Patent No. 7,659,097 and U.S. Patent Publication No. 2011 / 0045563.
[0136] In certain embodiments, the host cell can be an algal cell derived from, for example, green algae, red algae, gray algae, cleomelanin, euglena, chromophore, or dinoflagellate (see, e.g., Saunders & Warmbodt, "Gene Expression in Algae and Fungi, Including Yeast," (1993), National Agricultural Library, Beltsville, Md.). Exemplary plasmids or plasmid components for algal cells include those described in U.S. Patent Publication No. 2011 / 0045563.
[0137] In other embodiments, the host cell is a cyanobacterial, for example, any of the following groups classified based on morphology: Chlorococcales, Pleurocapsales, Oscillatoriales, Nostocales, Synechosystic, or Stigonematales (see, e.g., Lindberg et al., Metab. Eng. (2010) 12(1): 70-79). Exemplary plasmids or plasmid components for cyanobacterial cells include those described in U.S. Patent Publications 2010 / 0297749 and 2009 / 0282545 and International Patent Publication WO2011 / 034863.
[0138] In other embodiments, host cells may include other prokaryotes and eukaryotes, but are not limited to bacteria or yeast. Exemplary species include Escherichia coli., Saccharomyces cerevisiae, Saccharomyces kluyveri, Candida boidinii, Clostridium kluyveri, Clostridium acetobutylicum, Clostridium beijerinckii, Clostridium saccharoperbutylacetonicum, Clostridium perfringens, Clostridium difficile, Clostridium botulinum, Clostridium tyrobutyricum, Clostridium tetanomorphum, Clostridium tetani, Clostridium propionate, Clostridium tetanomorphum, Clostridium tetani ... propionicum, Clostridium aminobutyricum, Clostridium subterminale, Clostridium sticklandii, Ralstonia eutropha, Mycobacterium bovis, Mycobacterium tuberculosis, Porphyromonas gingivalis, Arabidopsis thaliana, Thermusthermophilus, Pseudomonas species, including Pseudomonas aeruginosa, Pseudomonas putida, Pseudomonas stutzeri, Pseudomonas fluorescens, Homo sapiens sapiens, Oryctolagus cuniculus, Rhodobacterspaeroides, Thermoanaerobacter brockii, Metallosphaera sedula, Leuconostoc mesenteroides, Chloroflexus aurantiacus, Roseiflexus castenholzii, Erythrobacter, Simmondsia chinensis, Acinetobacter species, including Acinetobacter calcoaceticus and Acinetobacter baylyi, Porphyromonas gingivalis, Sulfolobus tokodaii, Sulfolobus solfataricus, Sulfolobus acidocaldarius, Bacillus subtilis subtilis, Bacillus cereu, Bacillus megaterium, Bacillus brevis, Bacillus pumilus, Rattus norvegicus, Klebsiella pneumonia, Klebsiella oxytoca, Euglena gracilis, Treponema denticola, Moorella thermoacetica, Thermotogamaritima, Halobacterium salinarum, Geobacillus stearothermophilus, Aeropyrum pernix, Sus scrofa, Caenorhabditis elegans, Corynebacterium glutamicum glutamicum), Acidaminococcus fermentans, Lactococcus lactislactis, Lactobacillus plantarum, Streptococcus thermophilus, Enterobacter aerogenes, Candida, Aspergillus terreus, Pedicoccus pentosaceus, Zymomonas mobilus, Acetobacter pasteurians, Kluyveromyces lactis, Eubacterium barkeri, Bacteroides capillosus, Anaerotruncus colihominis, Natranaerobius thermophilusm, Campylobacter jejuni, Haemophilus influenzae, Serratia marcescens, Citrobacter amalonicidin amalonaticus, Myxococcus xanthus, Fusobacterium nuleatum, Penicillium chrysogenum, Nocardia iowensis, Nocardia farcinica, Streptomyces griseus, Schizosaccharomyces pombe, Geobacillus thermoglucosidasius, Salmonella typhimurium, Vibriocholera, Heliobacter pylori, Nicotiana tabacum, Oryza sativa, Haloferax mediterranei, Agrobacterium tumefaciens, Achromobacter denitrificans denitrificans), Fusobacterium nucleatumnucleatum), Streptomyces clavuligerus, Acinetobacter baumanii, Mus musculus, Lachanceakluyveri, Trichomonas vaginalis, Trypanosoma brucei, Pseudomonas stutzeri, Bradyrhizobium japonicum, Mesorhizobium loti, Bos taurus, Nicotiana glutinosa, Vibrio vulnificus, Selenomonasruminantium, Vibrio parahaemolyticus, Archaeoglobus fulgidus, Haloarcula marismortui), Pyrobaculumaerophilum, Mycobacterium smegmatis MC2155, Mycobacterium avium subsp. Paratuberculosis K-10, Mycobacterium marinum M, Tsukamurella paurometabola DSM20162, Cyanobium PCC7001, Dictyostelium discoideum AX4.
[0139] In certain embodiments, suitable organisms include Acinetobacter baumannii Naval-82, Acinetobacter sp. ADPl, Acinetobacter sp. strain M-1, Actinobacillus succinogenes 130Z, Allochromatium vinosum DSM180, Amycolatopsis methanolica, Arabidopsis thaliana, Atopobium parvulum DSM20469, Azotobacter vinelandii DJ, Bacillus alcalophilus ATCC27647, Bacillus azotoformans LMG9581, Bacillus coagulans coagulans)36D1, Bacillusmegaterium, Bacillus methanolicus MGA3, Bacillusmethanolicus PB1, Bacillus methanolicus PB-1, Bacillusselenitireducens MLS10, Bacillus smithii, Bacillussubtilis, Burkholderia cenocepacia, Burkholderia cepacia, Burkholderia multivorans, Burkholderia pyrrocinia, Burkholderiastabilis, Burkholderia thailandensis E264, Burkholderiales bacterium) Joshi_001, Campylobacter jejuni, Candida albicans, Candida boidiniiboidinii), Candida methylica, Carboxydothermus hydrogenoformans, Carboxydothermus hydrogenoformans Z-2901, Caulobacter sp. AP07, Chloroflexus aggregans DSM 9485, Chloroflexus aurantiacus J-10-fl, Citrobacter freundii, Citrobacter koseri ATCC BAA-895, Citrobacter youngae, Clostridium, Clostridium acetobutylicum, Clostridium acetobutylicum ATCC 824, Clostridium acidurici), Clostridium aminobutyricum, Clostridium asparagiforme DSM15981, Clostridium beijerinckii, Clostridium beijerinckii NCIMB 8052, Clostridium bolteae ATCC BAA-613, Clostridium carboxidivorans P7, Clostridium cellulovorans 743B, Clostridium difficile, Clostridium hiranonis DSM 13275, Clostridium hylemonae DSM 15053, Clostridium kluyveri, Clostridium kluyveri DSM 555, Clostridium ljungdahli, Clostridium ljungdahli DSM 13528, Clostridium methylpentosaceaemethylpentosum) DSM5476, Clostridium pasteurianum, Clostridium pasteurianum DSM525, Clostridium perfringens, Clostridium perfringens ATCC 13124, Clostridium perfringens str.13, Clostridium phytofermentans ISDg, Clostridium saccharobutylicum, Clostridium saccharoperbutylacetonicum, Clostridium saccharoperbutylacetonicum N1-4, Clostridium tetani, Corynebacterium glutamicum ATCC 14067, Corynebacterium glutamicum R, Corynebacterium sp.)U-96、Corynebacterium variabile、Cupriavidus necator N-1、Cyanobium PCC7001、Desulfatibacillum alkenivorans AK-01、Desulfitobacteriumhafniense、Desulfitobacterium metallireducens DSM 15288、Desulfotomaculum reducens MI-1、Desulfovibrio africanus str.Walvis Bay、Desulfovibrio fructosovorans JJ、Desulfovibrio vulgaris str.Hildenborough、Desulfovibrio vulgaris str.'Miyazaki F'、Dictyostelium discoideum AX4、Escherichia coli、Escherichia coli)K-12, Escherichia colicoli K-12MG1655, Eubacterium hallii DSM 3353, Flavobacterium frigoris, Fusobacterium nucleatumsubsp.Polymorphum ATCC 10953, Geobacillus sp. Y4.1MC1, Geobacillus thermodenitrificans NG80-2, Geobacter bemidjiensis Bem, Geobacter sulfurreducens, Geobacter sulfurreducens PCA, Geobacillus stearothermophilus DSM 2334, Haemophilus influenzae, Helicobacter pylori, Homo sapiens sapiens), Hydrogenobacter thermophilus, Hydrogenobacterthermophilus TK-6, Hyphomicrobiwn denitrificans ATCC 51888, Hyphomicrobiumzavarzinii, Klebsiella pneumoniae, Klebsiella pneumoniae subsp. Pneumoniae MGH 78578, Lactobacillusbrevis ATCC 367, Leuconostoc mesenteroides, Lysinibacillus fusiformis, Lysinibacillus sphaericus, Mesorhizobium nematodes loti)MAFF303099, Metallosphaerasedula, Methanosarcina acetivorans, Methanosarcina acetivorans C2A, Methanosarcinabarkeri), Methanosarcina mazei Tuc01, Methylobacter marinus, Methylobacterium extorquens, Methylobacterium extorquens AM1, Methylococcus capsulatas, Methylomonas aminofaciens, Moorellathernoacetica, Mycobacterium sp. strain JC1 DSM 3803, Mycobacterium avium subsp. Paratuberculosis K-10, Mycobacterium bovis BCG, Mycobacterium gastri, Mycobacterium marinum M, Mycobacterium smegmatis, Mycobacterium smegmatis smegmatis)MC2155, Mycobacterium tuberculosis, Nitrosopumilus solaria BD31, Nitrososphaera gargensis Ga9.2, Nocardia farcinica IFM 10152, Nocardia iowensis (sp.NRRL 5646), Nostoc sp. PCC 7120, Ogataea angusta, Ogataea parapolymorpha DL-1 (Hansenula polymorphaDL-1), Paenibacillus peoriae KCTC 3763, Paracoccus denitrificans, Penicillium chrysogenum, Photobacterium profundum 3TCK, Phytofermentans ISDg, Pichia pastoris, Picrophilustorridus DSM9790, Porphyromonas gingivalisgingivalis、Porphyromonas gingivalis W83、Pseudomonas aeruginosa PA01、Pseudomonas denitrificans、Pseudomonas knackmussii、Pseudomonas putida、Pseudomonas sp.、Pseudomonas syringaepv.Syringae B728a、Pyrobaculum islandicum DSM 4184、Pyrococcusabyssi、Pyrococcus furiosus、Pyrococcus horikoshii OT3、Ralstonia eutropha eutropha), Ralstonia eutropha H16, Rhodobacter capsulatus, Rhodobacter sphaeroides, Rhodobacter sphaeroides ATCC 17025, Rhodopseudomonas palustris, Rhodopseudomonas palustris CGA009, Rhodopseudomonas palustris DX-1, Rhodospirillum rubrum, Rhodospirillum rubrum ATCC 11170, Ruminococcus obeum ATCC 29174, Saccharomyces cerevisiae, Saccharomyces cerevisiae)S288c, Salmonella enterica, Salmonella enterica subsp. Enterica serovar Typhimurium str. LT2, Salmonella enterica typhimurium, Salmonella typhimuriumtyphimurium), Schizosaccharomyces pombe, Sebaldella termitidis ATCC33386, Shewanella oneidensis MR-1, Sinorhizobium meliloti 1021, Streptomyces coelicolor, Streptomyces griseus subsp. Griseus NBRC 13350, Sulfolobus acidocalarius, Sulfolobus solfataricus P-2, Synechocystis str. PCC 6803, Syntrophobacter fumaroxidans, Thauera aromatica, Thermoanaerobacter sp.) X514, Thermococcus kodakaraensis, Thermococcus litoralis, Thermoplasma acidophilum, Thermoproteus neutrophilus, Thermotoga maritima, Thiocapsarose persicina, Tolumonas auensis DSM 9187, Trichomonas vaginalis G3, Trypanosoma brucei, Tsukamurella paurometabola DSM 20162, Vibrio cholera, Vibrio harveyi ATCC BAA-1116, Xanthobacter autotrophicus Py2, Yersinia intermedia, or Zea mays.
[0140] In order to make the purpose, technical solutions and advantages of the embodiments of the present disclosure clearer, the technical solutions in the embodiments of the present disclosure will be clearly and completely described below in conjunction with the drawings in the embodiments of the present disclosure. Obviously, the described embodiments are part of the embodiments of the present disclosure, rather than all of the embodiments. In the absence of conflict, the following embodiments and the features in the embodiments can be combined with each other. The following embodiments are used to further illustrate the present disclosure, but should not be construed as limitations on the present disclosure. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principle of the present disclosure should be equivalent replacement methods and are included in the protection scope of the present disclosure.
[0141] Example 1: Construction of microbial cells capable of synthesizing progesterone
[0142] The gene was cloned into a Mycobacterium expression vector using conventional methods (e.g., Gibson assembly). The constructed plasmid contains a side chain cleavage P450 enzyme expression gene, and the expression vector comprises from the 5' end to the 3' end: (a) a first gene sequence encoding a non-native side chain cleavage P450 enzyme, the non-native side chain cleavage P450 enzyme being a Novosphingobium sp. PP1Y side chain cleavage P450 enzyme (SEQ ID NO: 18), or a Novosphingobium subterraneum side chain cleavage P450 enzyme CYP_9SPHN_1 (SEQ ID NO: 1) or CYP_9SPHN_2 (SEQ ID NO: 2), (b) a second gene sequence encoding a non-native ferredox protein, the non-native ferredox protein being a Spinacia oleracea ferredox protein FDX_SPIOL_1 (SEQ ID NO: 34). IDNO:5), and (c) a third gene sequence encoding a non-native ferredox protein reductase, wherein the non-native ferredox protein reductase is spinach (Spinacia oleracea) ferredox protein reductase FDXR_SPIOL_1 (SEQ ID NO:6). Each gene in the operon composed of the above genes is preceded by a ribosome binding site. Constitutive promoters Ptac or Ppms are used to control the expression of the operon. The expression vector backbone is from pJV53, which is a plasmid commonly used in recombination-mediated genetic modification (recombination modification), comprising a low-copy mycobacterium (Mycobacterium) replication origin, an Escherichia coli (E.coli) replication origin and a kanamycin selection marker. A total of 6 plasmids were constructed, as shown in Table 1.
[0143] Table 1. Plasmids used to construct microbial cells capable of synthesizing progesterone
[0144] Plasmids Plasmid description P001 Empty plasmid P002 Ppms>CYP_9SPHN_1>FDX_SPIOL_1>FDXR_SPIOL_1 P003 Ppms>CYP_9SPHN_2>FDX_SPIOL_1>FDXR_SPIOL_1 P004 Ppms>CYP_NOVAD_1>FDX_SPIOL_1>FDXR_SPIOL_1 P005 Ptac>CYP_9SPHN_1>FDX_SPIOL_1>FDXR_SPIOL_1 P006 Ptac>CYP_9SPHN_2>FDX_SPIOL_1>FDXR_SPIOL_1 P007 Ptac>CYP_NOVAD_2>FDX_SPIOL_1>FDXR_SPIOL_1
[0145] The plasmid was transformed into Mycobacterium neoaurum NRRLB-3805 by electroporation using conventional methods. The cells were plated on solid agar medium containing kanamycin for selection and cultured at 30°C for several days. Six individual colonies (numbered from 1 to 6, respectively) of each transformation reaction were inoculated into the wells of a 96-well plate containing a pre-seed medium. The 96-well plate was incubated in a shaker at 30°C for 3 days. The resulting culture was subcultured into a new 96-well plate containing a fresh seed medium. The plate was incubated in a shaker at 30°C for one day. The culture was transferred to a new 96-well plate containing 2-hydroxypropyl-β-cyclodextrin and 2 mg of 70% β-sitosterol. The plate was incubated in a shaker at 30°C for 3 days. After incubation, ethyl acetate was added to the plate. The plate was vortexed and shaken for extraction. Next, the plate was centrifuged and the organic layer was transferred to a new 96-well round-bottom plate and further diluted before being injected onto a gas chromatograph for analysis.
[0146] According to gas chromatography analysis, some strains accumulated progesterone, while no progesterone was observed in the wild-type strain transformed with an empty expression vector as a control strain ( Figure 1 ).
[0147] The strain No. 1 successfully transformed with the P007 plasmid capable of synthesizing progesterone was subcultured in a seed culture medium to obtain a seed culture, which was used as an inoculum for the primary fermentation in the following examples and comparative examples.
[0148] Example 2
[0149] Preparation of fermentation broth:
[0150] First level 500ml shake bottle fermentation
[0151] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0152] 3L fermentation tank fermentation conversion to produce progesterone
[0153] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, attapulgite 2.0g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is carried out at 30°C for 120 hours.
[0154] Downstream purification:
[0155] The fermentation liquid was harvested 739 g (containing 4.28 g of progesterone, as shown in the spectrum Figure 2 As shown), 369 g of ethyl acetate was added, and after sufficient stirring for 10 min, 423 g of ethyl acetate phase (containing 4.16 g of progesterone, as shown in the spectrum) was obtained. Figure 3 As shown), concentrated at 40°C and 60mbar until no liquid is distilled out to obtain 126g of concentrated liquid; 756g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 821g of acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was lowered to -10°C, the lower oil phase was separated, and 762g of acetonitrile phase after deoiling was obtained (containing 3.76g of progesterone, as shown in the spectrum Figure 4 ); 40 ℃, 40mbar concentrated acetonitrile phase until no liquid distilled out, to obtain an oily concentrated phase 7.30g; ethyl acetate 3.65g, n-heptane 7.30g, transferred to the crystallization kettle, lowered the temperature to -5 ℃, 6 hours later, suction filtered and washed the filter cake, the filter cake was transferred to a vacuum oven, 40 ℃, 100mbar overnight drying for 15 hours to obtain a primary crystallization crude product 3.27g; 16.08g of methanol was added to the crude crystallization product, heated to dissolve, the temperature was lowered to -5 ℃, 6 hours later, suction filtered and washed the filter cake, the filter cake was transferred to a vacuum oven, 40 ℃, 100mbar overnight drying for 15 hours to obtain a secondary crystallization fine product 2.96g (containing progesterone 2.90g, purity 98%, as shown in the spectrum Figure 5 shown).
[0156] Combine 30.56 g of the mother liquors of the primary crystallization and the secondary crystallization, concentrate at 40°C and 40 mbar until no liquid is distilled out, and obtain 1.01 g of an oily concentrated phase, add 0.50 g of ethyl acetate and 1.01 g of n-heptane, transfer to a crystallization kettle, transfer to a crystallization kettle, lower the temperature to -5°C, after 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100 mbar for 15 hours, and obtain 0.42 g of a primary crystallization crude product; add 1.68 g of methanol to the crude crystallization product, heat to dissolve, and then lower the temperature to -5°C. After 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100 mbar for 15 hours, and obtain 0.33 g of a secondary crystallization fine product (containing 0.32 g of progesterone, purity 97%).
[0157] Combining the two experiments, a total of 3.29 g of crystalline fine product (containing 3.22 g of progesterone) was obtained, and the yield of progesterone separation and purification reached 75%.
[0158] Example 3
[0159] Preparation of fermentation broth:
[0160] First level 500ml shake bottle fermentation
[0161] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0162] 3L fermentation tank fermentation conversion to produce progesterone
[0163] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, attapulgite 2.0g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is carried out at 30°C for 168 hours.
[0164] Downstream purification:
[0165] 1000 g of fermentation broth (containing 6.70 g of progesterone) was harvested, 500 g of ethyl acetate was added, and after sufficient stirring for 10 min, 581 g of ethyl acetate phase (containing 6.57 g of progesterone) was obtained by standing and stratification, which was concentrated at 40 ° C and 60 mbar until no liquid was distilled out to obtain 162 g of concentrated liquid; 972 g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 1056 g of acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was lowered to 5 ° C, the lower oil phase was separated, and 1004 g of acetonitrile phase after deoiling was obtained; the acetonitrile phase was concentrated at 40 ° C and 40 mbar until no liquid was distilled out to obtain 12.56 g of oily concentrated phase. ; Add 6.28g of ethyl acetate and 12.56g of n-heptane, transfer to the crystallization kettle, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 5.02g of primary crystallization crude product; add 20.08g of methanol to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 4.17g of secondary crystallization fine product (containing 4.13g of progesterone, purity 99%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone reaches 62%.
[0166] Example 4
[0167] Preparation of fermentation broth:
[0168] First level 500ml shake bottle fermentation
[0169] The culture medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30℃ for 48 hours. The 3L fermenter is fermented and converted to produce progesterone
[0170] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, attapulgite 3.0g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is carried out at 30°C for 168 hours.
[0171] Downstream purification:
[0172] 1000 g of fermentation broth (containing 7.01 g of progesterone) was harvested, 800 g of ethyl acetate was added, and after sufficient stirring for 10 min, 881 g of ethyl acetate phase (containing 6.94 g of progesterone) was obtained by standing and stratification, which was concentrated at 40 ° C and 60 mbar until no liquid was distilled out to obtain 166 g of concentrated liquid; 996 g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 1072 g of acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was lowered to 5 ° C, the lower oil phase was separated, and 1014 g of acetonitrile phase after deoiling was obtained; the acetonitrile phase was concentrated at 40 ° C and 40 mbar until no liquid was distilled out to obtain 12.76 g of oily concentrated phase. ; Add 6.38g of ethyl acetate and 12.76g of n-hexane, transfer to the crystallization kettle, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 5.34g of primary crystallization crude product; add 21.36g of methanol to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 4.35g of secondary crystallization fine product (containing 4.26g of progesterone, purity 98%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone reaches 61%.
[0173] Example 5
[0174] Preparation of fermentation broth:
[0175] First level 500ml shake bottle fermentation
[0176] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0177] 3L fermentation tank fermentation conversion to produce progesterone
[0178] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is maintained at 30°C for 144 hours.
[0179] Downstream purification:
[0180] 1000 g of fermentation broth (containing 5.25 g of progesterone) was harvested, 400 g of ethyl acetate was added, and after sufficient stirring for 10 min, 477 g of ethyl acetate phase (containing 5.09 g of progesterone) was obtained by standing and stratification, which was concentrated at 60°C and 100 mbar until no liquid was distilled out to obtain 164 g of concentrated liquid; 984 g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 1047 g of the acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was lowered to 5°C, the lower oil phase was separated, and 1024 g of the acetonitrile phase after deoiling was obtained; the acetonitrile phase was concentrated at 60°C and 40 mbar until no liquid was distilled out to obtain 20.68 g of the oily concentrated phase. g; add 10.34g ethyl acetate and 20.68g n-hexane, transfer to the crystallization kettle, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 3.02g of primary crystallization crude product; add 12.08g methanol to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 2.45g of secondary crystallization fine product (containing 2.38g of progesterone, purity 97%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone reaches 45%.
[0181] Example 6
[0182] Preparation of fermentation broth:
[0183] First level 500ml shake bottle fermentation
[0184] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0185] 3L fermentation tank fermentation conversion to produce progesterone
[0186] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, KOH is used to adjust the pH to 7.0-7.2, and the culture is carried out at 30°C for 168 hours.
[0187] Downstream purification:
[0188] 1000 g of fermentation broth (containing 5.42 g of progesterone) was harvested, 400 g of ethyl acetate was added, and after sufficient stirring for 10 min, 492 g of ethyl acetate phase (containing 5.26 g of progesterone) was obtained by standing and stratification, which was concentrated at 60 ° C and 100 mbar until no liquid was distilled out to obtain 155 g of concentrated liquid; 620 g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 678 g of acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was lowered to 10 ° C, the lower oil phase was separated, and 643 g of acetonitrile phase after deoiling was obtained; the acetonitrile phase was concentrated at 60 ° C and 40 mbar until no liquid was distilled out to obtain an oily concentrated phase 2 2.23g; add 22.23g of ethyl acetate, transfer to the crystallization kettle, lower the temperature to -5°C, after 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 1.86g of primary crystallization crude product; add 7.44g of ethyl acetate to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, after 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 1.27g of secondary crystallization fine product (containing 1.19g of progesterone, purity 94%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone reaches 22%.
[0189] Comparative Example 1
[0190] Preparation of fermentation broth:
[0191] First level 500ml shake bottle fermentation
[0192] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0193] 3L fermentation tank fermentation conversion to produce progesterone
[0194] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, attapulgite 2.0g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is carried out at 30°C for 120 hours.
[0195] Downstream purification:
[0196] 824 g of fermentation broth (containing 4.79 g of progesterone) was harvested, 412 g of ethyl acetate was added, and after sufficient stirring for 10 min, 475 g of ethyl acetate phase (containing 4.64 g of progesterone) was obtained by standing and stratification, which was concentrated at 40°C and 60 mbar until no liquid was distilled out to obtain 142 g of concentrated liquid; 852 g of methanol was used for 4 extractions, and the methanol phase was combined to obtain 965 g of methanol phase; the methanol phase was transferred to a jacketed glass reactor, the temperature was lowered to -10°C, the lower oil phase was separated, and 846 g of methanol phase after deoiling was obtained (containing 4.17 g of progesterone); the methanol phase was concentrated at 40°C and 40 mbar until no liquid was distilled out to obtain an oily concentrated phase 85.30g; add 47.65g ethyl acetate and 85.30g n-heptane, transfer to the crystallization kettle, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 0.43g of primary crystallization crude product; add 2.15g methanol to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, filter and wash the filter cake after 6 hours, transfer the filter cake to a vacuum oven, dry overnight at 40°C and 100mbar for 15 hours, and obtain 0.68g of secondary crystallization fine product (containing 0.66g of progesterone, purity 97%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone is 14%.
[0197] Comparative Example 2
[0198] Preparation of fermentation broth:
[0199] First level 500ml shake bottle fermentation
[0200] The medium formula is: glucose 2.5g / L, glycerol 10g / L, diammonium phosphate 3.5g / L, dipotassium hydrogen phosphate 0.5g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate heptahydrate 0.2g / L, zinc sulfate heptahydrate 0.01g / L, citric acid monohydrate 2.0g / L. The inoculation amount is 1% v / v, the shaking flask speed is 220rpm, and the culture is carried out at 30°C for 48 hours.
[0201] 3L fermentation tank fermentation conversion to produce progesterone
[0202] The culture medium formula is: glucose 10g / L, sodium dihydrogen sulfate 10g / L, diammonium phosphate 5.0g / L, dipotassium hydrogen phosphate 1.5g / L, magnesium sulfate heptahydrate 1.0g / L, aspartic acid 0.2g / L, citric acid monohydrate 2g / L. Castor oil 160g / L, lecithin 0.7g / L, attapulgite 2.0g / L, phytosterol 20g / L. The inoculation amount is 10% v / v, the stirring speed is 800-1000rpm, the ventilation ratio is 1.0, the pH is not controlled during the fermentation process, and the culture is carried out at 30°C for 168 hours.
[0203] Downstream purification:
[0204] 802 g of fermentation broth (containing 5.65 g of progesterone) was harvested, 401 g of ethyl acetate was added, and after sufficient stirring for 10 min, 472 g of ethyl acetate phase (containing 5.52 g of progesterone) was obtained by standing and stratification, which was concentrated at 40 ° C and 60 mbar until no liquid was distilled out to obtain 141 g of concentrated liquid; 846 g of acetonitrile was used for 4 extractions, and the acetonitrile phase was combined to obtain 927 g of acetonitrile phase; the acetonitrile phase was transferred to a jacketed glass reactor, the temperature was maintained at 25 ° C, the lower oil phase was separated, and 912 g of acetonitrile phase after deoiling (containing 5.47 g of progesterone) was obtained; the acetonitrile phase was concentrated at 40 ° C and 40 mbar until no liquid was distilled out to obtain an oily concentrated phase 4 2.36g; add ethyl acetate 21.18g, n-heptane 42.36g, transfer to the crystallization kettle, lower the temperature to -5°C, after 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C, 100mbar for 15 hours, and obtain 0.79g of primary crystallization crude product; add 3.95g of methanol to the crystallization crude product, heat and dissolve, lower the temperature to -5°C, after 6 hours, filter and wash the filter cake, transfer the filter cake to a vacuum oven, dry overnight at 40°C, 100mbar for 15 hours, and obtain 0.65g of secondary crystallization fine product (containing 0.64g of progesterone, purity 98%). Without recycling the crystallization mother liquor, the separation and purification yield of progesterone is 11%.
Claims
1. A method for extracting progesterone from phytosterol fermentation broth, characterized in that: The following steps are involved: S1: adding extraction solvent I to the phytosterol fermentation broth to obtain extraction phase I; S2: concentrating the extract phase I to obtain a concentrated phase I; S3: adding extraction solvent II to the concentrated phase I to obtain extraction phase II; S4: cooling the extraction phase II to -20 to 25° C., removing the lower oil phase, and obtaining the deoiled extraction phase II; S5: concentrating the deoiled extract phase II to obtain a concentrated phase II; S6: Purify the concentrated phase II by crystallization to obtain the target product.
2. The method according to claim 1, characterized in that The extraction solvent I is selected from one or more of esters, ethers, hydrocarbons, ketones, nitro compounds, thioethers and chlorinated solvents.
3. The method according to claim 1, characterized in that The extraction solvent II is selected from one or more of alcohols and acetonitrile. Preferably, the extraction solvent II is acetonitrile.
4. The method according to claim 1, characterized in that The step of low-temperature treatment of the extraction phase II comprises transferring the extraction phase II to a jacketed glass kettle, lowering the temperature to -20 to 25°C, preferably -10 to 10°C, more preferably -10 to 5°C, maintaining it for 2 to 4 hours, removing the lower oil phase, and obtaining the deoiled extraction phase II.
5. The method according to any one of claims 1 to 4, characterized in that: The weight ratio of the extraction solvent I to the phytosterol fermentation broth is 0.3-0.8:1, preferably 0.4-0.6:1, and more preferably 0.5:
1.
6. The method according to any one of claims 1 to 4, characterized in that: The concentration step of the extraction phase I is rotary evaporation, the rotary evaporation temperature is 30-80°C, preferably 40-60°C, more preferably 40-55°C, the rotary evaporation vacuum is 10-1000mbar, preferably 40-200mbar, more preferably 60-100mbar, and the rotary evaporation time is 1-2 hours.
7. The method according to any one of claims 1 to 4, characterized in that: The extractant II is added to the concentrated phase I in four portions, and the weight ratio of the extractant II added each time to the concentrated phase is 0.5 to 2.0:1, preferably 1.0 to 1.5:
1.
8. The method according to any one of claims 1 to 4, characterized in that: The concentration step of the deoiled extract phase II is rotary evaporation, the rotary evaporation temperature is 30-80°C, preferably 40-65°C, more preferably 40-60°C, the rotary evaporation vacuum is 10-1000mbar, preferably 20-200mbar, and the rotary evaporation time is 1-2 hours.
9. The method according to any one of claims 1 to 4, characterized in that: The crystallization purification step comprises: Adding crystallization solvent I and antisolvent I to the concentrated phase II, cooling and crystallizing to obtain a primary crystal crude product; Adding crystallization solvent II to the crude primary crystal product, cooling and crystallizing, to obtain a secondary crystal product.
10. The method according to claim 9, characterized in that The weight ratio of the crystallization solvent I to the concentrated phase II is 0.2 to 2.0:1, preferably 0.2 to 1.0:1, the weight ratio of the antisolvent I to the concentrated phase II is 0.5 to 5.0:1, preferably 0.5 to 1.0:1; the weight ratio of the crystallization solvent II to the primary crystallization crude product is 2.0 to 10.0:1, preferably 2.0 to 5.0:
1.
11. The method according to claim 9, characterized in that After adding the crystallization solvent I and the anti-solvent I to the concentrated phase II, the material is transferred to the crystallization kettle, and the temperature is reduced to -10 to 10°C, preferably -5 to 5°C, and maintained for 4 to 10 hours, preferably about 6 hours, and the crystallization liquid is filtered and washed to obtain a wet cake, which is vacuum dried at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain a primary crystallization crude product; the crystallization solvent II is added to the primary crystallization crude product, the temperature is reduced to -10 to 10°C, and maintained for 4 to 10 hours, preferably about 6 hours, and the crystallization liquid is filtered and washed to obtain a wet cake, which is vacuum dried at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain the secondary crystallization fine product.
12. The method according to claim 9, characterized in that The crystallization solvent I is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate, and the antisolvent I is selected from one or more of long-chain normal or isomeric alkanes.
13. The method according to claim 9, characterized in that The crystallization solvent II is selected from one or more of methanol, ethanol, isopropanol, ethyl acetate, acetone and n-butyl acetate.
14. The method according to any one of claims 1 to 13, wherein: After the crystallization purification step, the method further includes a step of applying the crystallization mother liquor.
15. The method according to claim 14, wherein the step of applying the crystallization mother solution comprises: (1) concentrating the crystallization mother liquor to obtain a concentrated phase III, adding a crystallization solvent I and an antisolvent I to the concentrated phase III, lowering the temperature to -10 to 10°C, maintaining for 4 to 10 hours, preferably about 6 hours, filtering the crystallization liquid to obtain a wet cake, and vacuum drying at 40 to 60°C and 100 to 1000 mbar for 10 to 15 hours to obtain a crude primary crystallization product; (2) Adding a crystallization solvent II to the crude product of the applied primary crystallization, reducing the temperature to -10 to 10°C, maintaining the temperature for 4 to 10 hours, preferably about 6 hours, filtering the crystallization liquid to obtain a wet filter cake, and vacuum drying to obtain a fine product of the applied secondary crystallization.
Citation Information
Cited By
Application of beta-sitosterol in preparation of vomitoxin detoxification agent
CN120459115A
